Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy versus palliative systemic chemotherapy in stomach cancer patients with peritoneal dissemination, the study protocol of a multicentre randomised controlled trial (PERISCOPE II)

W. J. Koemans*, R. T. van der Kaaij, H. Boot, T. Buffart, A. A. F. A. Veenhof, K. J. Hartemink, C. Grootscholten, P. Snaebjornsson, V. P. Retel, H. van Tinteren, S. Vanhoutvin, V. van der Noort, A. Houwink, C. Hahn, A. D. R. Huitema, M. Lahaye, M. Los, P. van den Barselaar, O. Imhof, A. AalbersG. M. van Dam, B. van Etten, B. P. L. Wijnhoven, M. D. P. Luyer, D. Boerma, J. W. van Sandick

*Bijbehorende auteur voor dit werk

OnderzoeksoutputAcademicpeer review

75 Citaten (Scopus)
201 Downloads (Pure)


BackgroundAt present, palliative systemic chemotherapy is the standard treatment in the Netherlands for gastric cancer patients with peritoneal dissemination. In contrast to lymphatic and haematogenous dissemination, peritoneal dissemination may be regarded as locoregional spread of disease. Administering cytotoxic drugs directly into the peritoneal cavity has an advantage over systemic chemotherapy since high concentrations can be delivered directly into the peritoneal cavity with limited systemic toxicity. The combination of a radical gastrectomy with cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) has shown promising results in patients with gastric cancer in Asia. However, the results obtained in Asian patients cannot be extrapolated to Western patients.The aim of this study is to compare the overall survival between patients with gastric cancer with limited peritoneal dissemination and/or tumour positive peritoneal cytology treated with palliative systemic chemotherapy, and those treated with gastrectomy, CRS and HIPEC after neoadjuvant systemic chemotherapy.MethodsIn this multicentre randomised controlled two-armed phase III trial, 106 patients will be randomised (1:1) between palliative systemic chemotherapy only (standard treatment) and gastrectomy, CRS and HIPEC (experimental treatment) after 3-4cycles of systemic chemotherapy.Patients with gastric cancer are eligible for inclusion if (1) the primary cT3-cT4 gastric tumour including regional lymph nodes is considered to be resectable, (2) limited peritoneal dissemination (Peritoneal Cancer Index

Originele taal-2English
Aantal pagina's8
TijdschriftBMC Cancer
StatusPublished - 6-mei-2019

Citeer dit